

response to Program Announcement #99000-D.

**Correction:** The meeting will not convene as a Special Emphasis Panel, as announced. Instead, applications received in response to Program Announcement #99000-D will be reviewed and evaluated by means of an internal objective review.

**Contact Person for More Information:** Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 11 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639-8025, e-mail eowl@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 24, 1999.

**John C. Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc 99-22485 Filed 8-25-99; 5:06 pm]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 1999 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Trends in STD Prevalence, Tuberculosis, and HIV Risk Behaviors Among Men Who Have Sex With Men: Correction

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announced the following meeting in the **Federal Register** of August 23, 1999, Volume 64, Number 162, Page 45971-45972.

**Name:** Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 1999 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Trends in STD Prevalence, Tuberculosis, and HIV Risk Behaviors among Men Who Have Sex with Men, Program Announcement #99000-E.

**Correction:** Please note the correct meeting date, as follows:

**Time and Date:** 8:30 a.m.-9 a.m., September 2, 1999 (Open), 9 a.m.-4:30 p.m., September 2, 1999 (Closed).

**CONTACT PERSON FOR MORE INFORMATION:** Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 11 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639-8025, e-mail eowl@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 24, 1999.

**John C. Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-22486 Filed 8-25-99; 4:49 pm]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 98C-1017]

#### International Association of Color Manufacturers; Withdrawal of Color Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a color additive petition (CAP 9C0264) proposing that the color additive regulations be amended to provide for the safe use of D&C Red No. 28 and its aluminum lake to color food and dietary supplements.

**FOR FURTHER INFORMATION CONTACT:** Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3071.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of November 25, 1998 (63 FR 65212), FDA announced that a color additive petition (CAP 9C0264) had been filed by the International Association of Color Manufacturers, c/o Daniel R. Thompson, P.C., 1620 I St., suite 925, Washington, DC 20006. The petition proposed to amend the color additive regulations to

provide for the safe use of D&C Red No. 28 and its aluminum lake to color food and dietary supplements. The International Association of Color Manufacturers has now withdrawn the petition without prejudice to a future filing (21 CFR 71.6(c)(2)).

Dated: August 12, 1999.

**Laura M. Tarantino,**

*Deputy Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 99-22478 Filed 8-27-99; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 99F-2907]

#### Alcide Corp.; Filing of Food Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Alcide Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of acidified sodium chlorite solutions as an antimicrobial agent on red meat parts and organs.

**DATES:** Written comments on the petitioner's environmental assessment by September 29, 1999.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Robert L. Martin, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204-0001, 202-418-3074.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9A4692) has been filed by Alcide Corp., 8561 154th Ave. NE., Redmond, WA 98052. The petition proposes to amend the food additive regulations in 21 CFR 173.325 to provide for the safe use of acidified sodium chlorite solutions as an antimicrobial agent on red meat parts and organs.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations issued under the National Environmental Policy Act

(40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 29, 1999, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 17, 1999.

**Alan M. Rulis,**

Director, Office of Premarket Approval,  
Center for Food Safety and Applied Nutrition.  
[FR Doc. 99-22475 Filed 8-27-99; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Blood Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Blood Products Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on September 16, 1999, 8 a.m. to 4:30 p.m. and September 17, 1999, from 8 a.m. to 12:30 p.m.

*Location:* Ramada Inn, Embassy Ballroom, 8400 Wisconsin Ave., Bethesda, MD.

*Contact Person:* Linda A. Smallwood, Center for Biologics Evaluation and Research (HF-350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-3514, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On September 16, 1999, the following committee updates are tentatively scheduled: (1) Summary of the August 26 to 27, 1999, Public Health Service (PHS) Advisory Committee on Blood Safety and Availability meeting; (2) summary of the July 21, 1999, Workshop on Donor Suitability: Donor History of Hepatitis; and (3) guidance document on revised precautionary measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and new variant Creutzfeldt-Jakob Disease (nvCJD) by blood and blood products. Other committee updates will be scheduled if the need arises. In the morning, the committee will hear and discuss an informational presentation on strategies for increasing the blood supply and discuss and provide recommendations on nucleic acid testing of blood donors for human parvovirus B-19. In the afternoon, the committee will hear an informational presentation on antigen/antibody testing for malaria.

On September 17, 1999, the committee will sit as a medical device panel for the reclassification of human immunodeficiency virus (HIV) drug sensitivity assays.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 7, 1999. Oral presentations from the public will be scheduled from approximately 10 a.m. to 10:30 a.m.; 11:30 a.m. to 12 noon; and 3 p.m. to 3:30 p.m. on September 16, 1999, and from 9 a.m. to 11 a.m. on September 17, 1999. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 7, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 22, 1999.

**Linda A. Suydam**

Senior Associate Commissioner

[FR Doc. 99-22480 Filed 8-27-99; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Advisory Committee for Pharmaceutical Science; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Advisory Committee for Pharmaceutical Science.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on September 23 and 24, 1999, 8:30 a.m. to 5 p.m.

*Location:* Center for Drug Evaluation and Research Advisory Committee conference room, 5630 Fishers Lane, Rockville, MD.

*Contact Person:* Kimberly Littleton Topper at [topperk@cder.fda.gov](mailto:topperk@cder.fda.gov) or Angie Whitacre at [whitacre@cder.fda.gov](mailto:whitacre@cder.fda.gov), Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12539. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On September 23, 1999, the committee will discuss individual bioequivalence-criteria for equivalence comparisons. On September 24, 1999, the committee will discuss clinical pharmacology-pharmacokinetic/pharmacodynamic issues in drug development and research issues in nonclinical studies.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 8, 1999. Oral